Daniel Gil-Alós
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel Gil-Alós has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Abhilash Barpanda
Department of Laboratory Medicine, University of California
1 shared publication Adaia Albasanz-Puig
Department of Infectious Diseases, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, 08035, Barcelona, Spain, 2 Department of Medicine, Universitat Autònoma de Barce, Barcelona, Spain
1 shared publication- Adila Izgutdina
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
1 shared publication - Adolfo Aleman
Icahn School of Medicine at Mount Sinai, New York, New York, United States
1 shared publication - Adrián Fernández
Advanced Therapies Manufacturing Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
1 shared publication Ajai Chari
Univeristy of California, San Francisco, San Francisco, California, United States
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
Progressive Multifocal Leukoencephalopathy in Lymphoid Malignancies: A Multicenter GELTAMO Case Series
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessProgressive Multifocal Leukoencephalopathy in Lymphoid Malignancies: A Multicenter GELTAMO Case Series
- Open Access
- 28 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2933
Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis
Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.
- 28 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2933
Open AccessMass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis
Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.
- Open Access
- 20 November 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (2) , 101968
GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia
- 20 November 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (2) , 101968
Open AccessGMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia
- Open Access
- 13 May 2025
- Published by American Society of Hematology in Blood
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.
- 13 May 2025
- Published by American Society of Hematology in Blood
Open AccessTargeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.